Head and Neck Cancer Trial, Recruiting NCT06682442 Sponsor: University of California, San Francisco Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06682442
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat), confirmed by a tissue or cell sample from the tumor or nearby lymph nodes.
  • Your cancer is linked to the Epstein-Barr virus (EBV), shown by a detectable level of EBV in your blood through a lab test.
  • Your cancer is at Stage III or Stage IVA (meaning it is locally advanced but has not spread to distant parts of the body), confirmed through a physical exam and specific imaging scans (such as MRI, CT, or PET/CT scans).
  • You have already started or are planning to start chemotherapy containing platinum (a common cancer drug) before radiation treatment.
  • You are planning to receive a precise type of radiation therapy called IMRT along with platinum-based chemotherapy at the same time.
  • Additional immunotherapy treatment after chemoradiation is allowed.
  • You are 18 years of age or older.
  • You are generally able to carry out daily activities, either fully or with some limitations (confirm with trial site what level of activity is required).
  • If you are living with HIV, you are on effective HIV treatment.
  • If you have chronic hepatitis B, you are on the appropriate suppressive treatment if your doctor has recommended it.
  • If you have had hepatitis C, you are currently being treated for it or have already been successfully treated and cured.
  • You have had or currently have another type of cancer, but it is not expected to interfere with this trial's treatments or results (confirm with trial site).
  • If you are able to have children, you agree to use reliable birth control during the study and for at least 60 days after your last radiation treatment, and you will notify your doctor right away if you or your partner becomes pregnant.
  • You are able to understand the study information and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have previously received chemotherapy specifically for nasopharyngeal carcinoma, other than induction chemotherapy (the initial chemotherapy given before radiation); note that prior chemotherapy for a completely different cancer is allowed.
  • You have previously had radiation therapy to the nasopharynx or nearby areas in a way that would overlap with the radiation planned for this trial.
  • You have taken part in another clinical trial and received an experimental drug or used an experimental device within the past 4 weeks.
  • You have a serious ongoing health condition, such as a major physical or mental illness that could prevent you from completing the treatment or understanding its risks, a recent unstable heart condition or hospitalization for heart or circulation problems in the last 12 months, a recent severe lung condition requiring hospitalization in the last 30 days, or an active serious infection currently requiring intravenous (IV) antibiotics.
  • If you are able to become pregnant, you do not have a documented negative pregnancy test on record.
  • You have any personal situation or health condition that, in the opinion of the study doctor, would make it unsafe or difficult for you to participate in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sue Yom, MD, PhD, University of California, San Francisco

Phone: 877-827-3222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 March 2025
Est. completion
31 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Progression-Free Survival Rate (PFS) at 2 years post radiation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov